Upadacitinib

An article about the medication Upadacitinib

Upadacitinib
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Upadacitinib is a medication used in the treatment of several inflammatory conditions. It is classified as a Janus kinase inhibitor, which works by interfering with the signaling pathways that lead to inflammation.

Mechanism of Action

Upadacitinib functions by selectively inhibiting the activity of Janus kinase (JAK) enzymes. These enzymes are crucial in the signaling pathways of various cytokines and growth factors that are involved in hematopoiesis and immune function. By inhibiting JAKs, upadacitinib reduces the inflammatory response that is characteristic of autoimmune diseases.

Medical Uses

Upadacitinib is primarily used in the treatment of:

• Rheumatoid arthritis
• Psoriatic arthritis
• Atopic dermatitis
• Ulcerative colitis

Rheumatoid Arthritis

In patients with moderate to severe rheumatoid arthritis, upadacitinib is used to reduce symptoms and improve physical function. It is often prescribed when patients have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).

Psoriatic Arthritis

For individuals with active psoriatic arthritis, upadacitinib helps in reducing joint pain and swelling, as well as improving skin symptoms associated with the condition.

Atopic Dermatitis

Upadacitinib is also indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents who are candidates for systemic therapy.

Ulcerative Colitis

In the context of ulcerative colitis, upadacitinib is used to induce and maintain clinical remission in patients with moderate to severe disease.

Side Effects

Common side effects of upadacitinib include:

• Upper respiratory tract infections
• Nausea
• Headache
• Hypertension

Serious side effects may include:

• Increased risk of serious infections
• Thrombosis
• Liver enzyme elevations

Administration

Upadacitinib is administered orally, typically once daily. The dosage may vary based on the specific condition being treated and the patient's response to the medication.

Related pages

• Janus kinase inhibitor
• Rheumatoid arthritis
• Psoriatic arthritis
• Atopic dermatitis
• Ulcerative colitis

• 

  Upadacitinib